Optimi Health (OPTH) stock price is $2.25, up 0.90% on the day, as of Nov 13, 2026. It has a market cap of $9.67Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap9.67 Mn
P/E-1.60
FCF (Yr)-1.88 Mn
ROA (Yr)-37.33
EV to EBIT0.11
Net Income (Yr)-2.66 Mn
Enterprise Value-791,462.39
Add ratio to table…
About
Optimi Health is a Canadian GMP compliant pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. The company specializes in MDMA and psilocybin derived from botanical sources. It operates two 10 000 square foot production facilities in Princeton British Columbia and holds a Drug Establishment Licence and a Dealer Licence that allow it to possess produce assemble sell and deliver psychedelic substances within…
Optimi Health is a Canadian GMP compliant pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. The company specializes in MDMA and psilocybin derived from botanical sources. It operates two 10 000 square foot production facilities in Princeton British Columbia and holds a Drug Establishment Licence and a Dealer Licence that allow it to possess produce assemble sell and deliver psychedelic substances within the regulatory framework set by Health Canada.
Optimi Health generates revenue primarily from the sale of GMP certified MDMA and psilocybin capsules to authorized prescribers in Australia under the Authorised Prescribers Scheme and to clinical trial sponsors in countries such as Canada Israel and New Zealand. The company also earns revenue from its analytical laboratory by offering third party testing services for psychedelic compounds. Supply agreements with partners such as Mind Medicine Australia KMT Pharmaceuticals and Mātai Medical Research provide additional streams of income.
Optimi Health holds a differentiated position in the psychedelic pharmaceutical sector as one of the few companies with a Drug Establishment Licence that enables commercial supply of GMP MDMA and psilocybin products in regulated markets such as Australia. Its competitive advantages include vertical integration of cultivation extraction formulation and packaging two purpose built facilities and early mover status in the Australian prescription market. Key competitors include Compass Pathways MindMed Atai Life Sciences and Lykos Therapeutics which remain primarily in clinical or pre commercial stages.
The company serves patients treated under Australia’s Authorised Prescribers Scheme psychiatric clinics and hospitals as well as clinical trial sponsors and research institutions. Specific customer names mentioned in the filing include Mind Medicine Australia Limited KMT Pharmaceuticals Pty Ltd Sunshine Earth Labs Ltd Mātai Medical Research Institute ATMA CENA Healthcare Solutions and Tel Aviv University.
Sector:HealthcareSector rationaleOptimi Health is a GMP compliant pharmaceutical drug manufacturer that produces and sells MDMA and psilocybin capsules to authorized prescribers and clinical trial sponsors. Its core revenue comes from the manufacture and distribution of medical products, which falls directly under the Pharmaceuticals and Drug Distribution industries within the Healthcare sector.Industries:PharmaceuticalsPharmaceuticalsPrimaryOptimi Health is a GMP compliant pharmaceutical manufacturer that produces and sells branded prescription psychedelic substances, specifically MDMA and psilocybin capsules. Its revenue is derived from sales to authorized prescribers and clinical trial sponsors.Diagnostic LabsDiagnostic LabsSecondaryThe company operates an analytical laboratory that generates revenue by offering third-party testing services for psychedelic compounds.Classified using BQ-MICSCIK: 0002027329
Peer percentiles
How Optimi Health ranks
Ranked against the 695 companies in Pharmaceuticals and Biotechnology·58 metrics · as of Nov 14, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last